It’s Official: FDA Approval Does Not Equal CMS Coverage
This article was originally published in RPM Report
Medicare’s updated coverage determination policy spells out in black-and-white that the payor agency does not feel that the law requires it to pay for FDA-approved products used on-label.
You may also be interested in...
CMS’ coverage of cancer drugs isn’t as automatic as you think. Here’s how the Medicare agency sees it.
Medicaid’s pharmacy director says the Biogen Alzheimer’s drug is ‘currently a covered outpatient drug.’ As the payer of last resort, Medicaid could find itself significantly impacted by a Medicare national coverage decision.
A review of drugs and supplemental uses since the project’s inception shows roughly one-third of the products reviewed have been NMEs.